Guidelines Regarding the Sale of Dimenhydrinate
Issued November 2014

1. As a Schedule III drug, dimenhydrinate may be sold from the self-selection area of the pharmacy. However, even if sold from this location, registrants and other staff should be aware of the sales of dimenhydrinate and the pharmacist-in-charge should be alerted to any potential concerns or issues.

2. If evidence of misuse or abuse of dimenhydrinate is detected, pharmacists-in-charge are encouraged to restrict the sale of dimenhydrinate to Schedule II status (i.e. no patient self-selection, mandatory direct pharmacist involvement in the sale).

3. Dimenhydrinate in package sizes greater than 30 tablets, or 100ml of liquid should not be sold from the self-selection area of the pharmacy and should only be sold pursuant to a prescription, or following pharmacist assessment and documentation on the patient profile.